Investing in Telepatia

Andreessen Horowitz (a16z) led a $33 million Series A investment in Telepatia, an AI-native clinical platform for Latin America that combines AI documentation, clinical decision support, and AI healthcare employees. The platform, launched in July 2025, has deployed across 25+ hospital systems in Brazil, Colombia, and Mexico, reaching 14 million patients and preventing 60,000 medical errors in real time. The investment aims to address the region's severe clinician shortage by leapfrogging traditional healthcare infrastructure.

Investing in Telepatia a16z leads Telepatia's Series A America https://www.a16z.news/t/america | Tech https://www.a16z.news/t/technology | Opinion https://www.a16z.news/t/opinion | Culture https://www.a16z.news/t/culture | Charts https://www.a16z.news/t/charts Nicolás Abad’s father was the kind of doctor patients never forget. A physician in Colombia, he became known as “Telepatia” because of his uncanny ability to understand what was wrong before patients had even finished explaining their symptoms. He died at 58 from a preventable drug interaction – just days before the release of ChatGPT, which helped usher in a new generation of AI capable of catching this type of risk. Today, Nico is building the product that could have helped save his father’s life, and that his father would have loved as a doctor. We’re excited to announce our lead investment in Telepatia’s $33 million Series A. Latin America has 700 million people, but a severe shortage of clinicians. The region has 43% fewer physicians and 65% fewer nurses per capita than OECD countries on average. Where the United States has spent decades piling software on top of a fractured system and created a new kind of mess, Latin America has the advantage of starting from a clean slate, and the potential to leapfrog the clinician shortage entirely. Telepatia is building the AI-native clinical platform for Latin America. Its platform combines AI documentation, clinical decision support, and a growing suite of AI healthcare employees—including AI doctors, nurses, and auditors—integrated across hospital systems and trained on clinical guidelines, peer-reviewed literature, and local institutional protocols. Since launching in July 2025, the platform has deployed across 25+ hospital systems in Brazil, Colombia, and Mexico, reaching 14 million patients. Doctors use it all day. Protocol adherence has risen from 84% to 99% after deployment with physicians recovering 1.7 hours daily – time they now spend with patients. Telepatia has already prevented 60,000 medical errors in real time, allowing physicians to adjust course immediately. Take it from the customers themselves. “The real test of any clinical tool is whether doctors actually use it,” says José Henrique Dias Salvador, CEO of Mater Dei in Brazil. “Our physicians use Telepatia eight hours a day. We’ve never seen adoption like that.” The top 100 health institutions in Latin America employ 50% of physicians. This concentration means that a single platform can achieve outsized distribution once it breaks into the top systems. Win the right logos, and distribution compounds in ways that simply aren’t possible in more saturated markets. Telepatia is achieving this. We are joined in this round by Palantir CTO Shyam Sankar, Rappi founder Simón Borrero, and Nubank founder David Vélez, three leaders who have built and scaled transformative technology in complex industries across Latin America and the world. Nico’s father had a wall covered with portraits of Nobel laureates he admired – scientists like Allvar Gullstrand and Richard Feynman whose discoveries changed the course of medicine and science. We asked Nico what winning a Nobel Prize would feel like. He said: earning a place on that wall. Nico’s goal is to win the first Nobel Prize in Medicine awarded to a Latin American since 1984. As he puts it, “Recent Nobel Prizes in Physics and Chemistry have gone to breakthroughs powered by AI. We believe Medicine is next.” This newsletter is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. Furthermore, this content is not investment advice, nor is it intended for use by any investors or prospective investors in any a16z funds. This newsletter may link to other websites or contain other information obtained from third-party sources - a16z has not independently verified nor makes any representations about the current or enduring accuracy of such information. If this content includes third-party advertisements, a16z has not reviewed such advertisements and does not endorse any advertising content or related companies contained therein. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z; visit https://a16z.com/investment-list/ for a full list of investments. Other important information can be found at a16z.com/disclosures. You’re receiving this newsletter since you opted in earlier; if you would like to opt out of future newsletters you may unsubscribe immediately.